PeptidePeptideHGH fragmentFat-loss (claimed)

HGH Fragment 176-191

Also known as HGH Frag 176-191 · Frag 176-191 · Growth hormone fragment 176-191

Written by enwyReviewed 15 Jul 20261 sources0 comments

HGH Fragment 176-191 is the short C-terminal region of human growth hormone marketed as a fat-loss peptide. It is closely related to AOD-9604 (which adds a tyrosine to this sequence). Human evidence is minimal; the fat-loss claims rest on preclinical rodent lipolysis studies and marketing rather than controlled human trials.

01 Overview

The 176-191 fragment corresponds to the part of the growth hormone molecule thought to carry its lipolytic activity, and it was the basis for the more-developed analogue AOD-9604. Vendors sell it as a way to reduce body fat, particularly abdominal fat, without the systemic effects of full growth hormone.

Supporting data are largely from rodent adipocyte and animal studies showing lipolytic and anti-lipogenic effects. There are no robust human clinical trials of this exact peptide, and the most closely related, best-studied analogue (AOD-9604) failed to beat placebo for weight loss in people. Human fat-loss claims are therefore unproven.

02 Mechanism

The fragment is proposed to stimulate lipolysis and inhibit fat accumulation via a growth-hormone-like C-terminal action, reportedly without effects on IGF-1 or glucose; human relevance unconfirmed.

03 Dosing

Tier	Dose	Route	Notes
Anecdotal	250–500 mcg/day	SubQ	Forum protocols, often split doses fasted. No validated dosing.

04 Effects

Effect	Magnitude	Evidence
LipolysisFat-mobilising activity in preclinical models; not confirmed in humans.	Seen in rodent adipocytes	Preclinical
Claimed abdominal fat lossMarketed claim without controlled human support; related analogue failed in trials.	Unquantified	Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence	Countermeasures
Injection-site reactionsLocal redness or irritation.	Mild	Common	Anecdotal
Unknown purity / contamination riskResearch-chemical peptides vary in purity and may contain contaminants.	Moderate	Product-dependent	Unconfirmed

06 Legal status

United States

Not FDA-approved; research chemical

Not approved for human use; WADA-prohibited in sport. · as of Jan 2026

07 References

Lipolytic activity of the C-terminal fragment of human growth hormonePreclinical lipid metabolism studies

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.